CASI Pharmaceuticals, Inc. (CASIF) stock
CASIFOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on May 15, 2026Score 1/30
$0.10+0.00 (0.00%)
Close on Oct 19, 2026Market cap –P/E –Yield –
CASI Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
For fiscal 2025 it was -$43.81M. The highest annual figure on record is -$22.58M in fiscal 2023.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$43.81M | – |
| FY2024 | Dec 31, 2024 | -$38.32M | – |
| FY2023 | Dec 31, 2023 | -$22.58M | – |
| FY2022 | Dec 31, 2022 | -$32.83M | – |
| FY2021 | Dec 31, 2021 | -$41.02M | – |
| FY2020 | Dec 31, 2020 | -$52.18M | – |
See a number that looks wrong?